OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Sekeres on the Need for Novel Combinations in Higher-Risk MDS/CMML and Low-Blast AML

June 4th 2020

Mikkael A. Sekeres, MD, discusses the need for novel combinations in higher-risk myelodysplastic syndrome (MDS)/chronic myelomonocytic leukemia (CMML) and low-blast acute myelogenous leukemia (LB AML).

Dr. Gwin on the Safety of α-TEA Plus Trastuzumab in Recurrent HER2+ Breast Cancer

June 3rd 2020

William R. Gwin III, MD, discusses the safety profile of alpha-tocopheryloxyacetic acid in combination with trastuzumab in recurrent HER2-positive metastatic breast cancer.

Dr. Rotow on Results of a Phase 1/2 Trial With Osimertinib/Gefitinib in EGFR-Mutant NSCLC

June 3rd 2020

Julia K. Rotow, MD, discusses the results of an ongoing phase 1/2 trial evaluating the safety and efficacy of osimertinib in combination with gefitinib as a first-line treatment for patients with stage IV EGFR-mutant non–small cell lung cancer.

Dr. Lonial on the Importance of Early Intervention in High-Risk Smoldering Myeloma

June 3rd 2020

Sagar Lonial, MD, FACP, discusses the benefits of early intervention in high-risk smoldering multiple myeloma.

Dr. Cortes on Future Directions in MPNs

June 3rd 2020

Jorge E. Cortes, MD, discusses challenges with ruxolitinib in myeloproliferative neoplasms.

Dr. Lee on Cirmtuzumab/Ibrutinib Dosing in MCL and CLL

June 3rd 2020

Hun Ju Lee, MD, discusses dosing of the combination of the investigational ROR1 inhibitor cirmtuzumab and ibrutinib in mantle cell lymphoma and chronic lymphocytic leukemia.

Dr. McKay on Adapting Treatment for Patients With Cancer in COVID-19 Era

June 3rd 2020

Rana R. McKay, MD, discusses adapting treatment for patients with cancer during the coronavirus disease 2019 pandemic.

Dr. Andre on the Rationale for the KEYNOTE-177 Trial in mCRC

June 3rd 2020

Thierry Andre, MD, discusses the rationale for the phase 3 KEYNOTE-177 trial in metastatic colorectal cancer.

Dr. DiNardo on the Role of Venetoclax in AML

June 3rd 2020

Courtney DiNardo, MD, MSCE, discusses the role of venetoclax (Venclexta) in acute myeloid leukemia (AML).

Dr. Zakashansky on the Benefit of Maintenance Olaparib in BRCA+ Ovarian Cancer

June 3rd 2020

Konstantin Zakashansky, MD, discusses final overall survival data from the phase 3 SOLO2 trial evaluating maintenance olaparib (Lynparza) in platinum-sensitive, relapsed ovarian cancer with a BRCA mutation.

Dr. Katz on Redefining Risk Assessment in Prostate Cancer With 17-Gene Oncotype DX GPS

June 3rd 2020

Aaron E. Katz, MD, FACS, discusses re-classifying low-risk prostate scores with the 17-gene Oncotype DX Genomic Prostate Score.

Dr. Kumar on Treatment Discontinuation in the ENDURANCE Trial in Multiple Myeloma

June 3rd 2020

Shaji K. Kumar, MD, discusses the rate of treatment discontinuation in the phase 3 ENDURANCE trial in newly diagnosed multiple myeloma.

Dr. Sfakianos on the Utility of Adjuvant Therapy in Bladder Cancer Management

June 3rd 2020

John P. Sfakianos, MD, discusses the utility of adjuvant therapy in bladder cancer management.

Dr. Hamdan on Choosing Among ABVD Versus A+AVD in Hodgkin Lymphoma

June 2nd 2020

Ayad Hamdan, MD, discusses factors to consider when choosing between brentuximab vedotin (Adcetris), doxorubicin, vinblastine, and dacarbazine versus AVD plus bleomycin in patients with Hodgkin lymphoma.

Dr. Overman on Potential Application of ctDNA in CRC

June 2nd 2020

Michael J. Overman, MD, discusses potential applications for circulating tumor DNA in colorectal cancer.

Dr. Scagliotti on Preventive Measures to Reduce COVID-19 Risk in Oncology

June 2nd 2020

Giorgio Vittorio Scagliotti, MD, PhD, discusses the precautionary measures implemented in clinical practice to protect patients with cancer from COVID-19.

Dr. Poveda on the Results of the SOLO2 Trial in Ovarian Cancer

June 2nd 2020

Andres Poveda, MD, discusses the results of the phase 3 SOLO2 trial in advanced ovarian cancer.

Dr. Richardson on Phase 1 Data With CC-92480 in Multiple Myeloma

June 2nd 2020

Paul G. Richardson, MD, discusses phase 1 data (NCT03374085) with CC-92480 in multiple myeloma.

Dr. Wang on Correlative Data From the ZUMA-2 Trial in MCL

June 2nd 2020

Michael Wang, MD, discusses correlative data from the phase 2 ZUMA-2 trial in mantle cell lymphoma (MCL).

Dr. Rodriguez-Abreu on the Final Analysis of the KEYNOTE-189 Trial in NSCLC

June 2nd 2020

Delvys Rodriguez-Abreu, MD, discusses the final analysis of the phase 3 KEYNOTE-189 study in metastatic nonsquamous non–small cell lung cancer.

NEXT PAGE
PREVIOUS PAGE